Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Short term Debt (2016 - 2026)

Amphastar Pharmaceuticals has reported Short term Debt over the past 13 years, most recently at $1.6 million for Q4 2025.

  • For Q4 2025, Short term Debt rose 601.28% year-over-year to $1.6 million; the TTM value through Dec 2025 reached $1.6 million, up 601.28%, while the annual FY2025 figure was $1.6 million, 601.28% up from the prior year.
  • Short term Debt for Q4 2025 was $1.6 million at Amphastar Pharmaceuticals, up from $923000.0 in the prior quarter.
  • Over five years, Short term Debt peaked at $12.9 million in Q2 2023 and troughed at $224000.0 in Q1 2025.
  • A 5-year average of $2.7 million and a median of $1.7 million in 2022 define the central range for Short term Debt.
  • Biggest five-year swings in Short term Debt: crashed 98.07% in 2024 and later surged 601.28% in 2025.
  • Year by year, Short term Debt stood at $2.2 million in 2021, then skyrocketed by 38.33% to $3.0 million in 2022, then crashed by 85.69% to $436000.0 in 2023, then crashed by 46.33% to $234000.0 in 2024, then surged by 601.28% to $1.6 million in 2025.
  • Business Quant data shows Short term Debt for AMPH at $1.6 million in Q4 2025, $923000.0 in Q3 2025, and $927000.0 in Q2 2025.